Clinical Trials
Five Facts About Psychedelics for Mental Health
As the incidence of mental health issues increases around the world, most recently exacerbated by the COVID-19 pandemic that has pushed depression to nearly triple the rate
Top 5 Scientific Resources in CNS Clinical Trials
Scientific Resources in CNS Clinical Trials
Altasciences has an extensive understanding of psychiatric and neurologic disorders, stemming from our decades of conducting complex studies in various therapeutic indications impacting the central nervous system.
Here are some of our most insightful scientific resources in the area of CNS drug development:
- The Altascientist: Central Nervous System
Early phase development of CNS-acting drugs is a complex, challenging undertaking. In this article, we provide a detailed overview of the multiple facets you need to consider during the planning and conduct of your CNS-active drug development. Learn More
- The Altascientist: CNS, Psychedelics and Other Schedule I Drugs
In this scientific journal, we uncover the regulatory environment and challenges, the required preclinical and clinical studies specific to Schedule I or Class I (CI) drugs, and the manufacturing considerations for CNS-active drugs. Learn More
- The Altascientist: Studying the Effects of Drugs on Driving
Driving simulation studies are required by the FDA when preclinical and early clinical studies show that a drug may cause somnolence or impair cognition. Discover the challenges of driving simulation clinical testing. Learn More
- Webinar: Navigating the Abuse Potential Evaluation of CNS-active Drugs for EU and U.S. Submissions
In this on-demand webinar, we discuss the key considerations for delivering an integrated preclinical and clinical abuse potential drug development evaluation that meets EMA and FDA regulatory requirements. Watch Now
- Webinar: Inside the Pharmacodynamic Toolbox: How Questionnaires, Models, and Tests of Cognition Can Accelerate the Development of CNS-active Drugs
This session explores the flexible selection of pharmacodynamic measures to enhance the pharmacology, safety, and efficacy. Watch Now
Speak with an expert today to learn more about our CNS solution.
Have five more minutes? Check out these webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Seamless Bioanalytical Transition from Preclinical to Clinical, and Beyond
Seamless Bioanalytical Transition
Altasciences’ scientists move in unison with you, collaboratively, accurately, and efficiently, from preclinical to clinical, and beyond. Our team of over 260 bioanalytical scientific veterans is strategically located across North America, and has experience with a wide spectrum of biological matrices in both animal and humans.
Driven by your assay requirements, our program support includes LC-MS/MS, LBA OR HYBRID LBA/LC-MS/MS ASSAY platforms for:
|
|
Have 5 minutes? You may also be interested in the following:
- Assay List — Over 685 Assays covering 650 Molecules
- The Altascientist — Validation of Immunogenicity Assays
- Webinar — Development of a Cell-Based Assay for Dual Purposes: to Support Drug Potency and Immunogenicity Characterization
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
How Novel Data-Driven Treatments Are Improving Patient Care
PODCAST — How Novel Data-Driven Treatments Are Improving Patient Care
Special guest Dr. Michael Winlo, Managing Director at Emyria, joins us for a very insightful conversation about their unique programs and new patient care models. Emyria is a biotech company that brings together patients, clinicians, researchers, and medical innovators to develop data-driven, novel treatments for patients in need, including cannibidiol formulations.
Have questions? Speak with one of our experts.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
One Integrated Solution for Meeting Your Preclinical to Clinical Drug Development Needs
Three Key Advantages of Conducting Early Phase Clinical Trials in North America: An Overview of the Webinar “A Hop Across the Pond”
Regulatory processes can be challenging, and potential solutions can be found in broadening your focus to include clinical sites in the U.S. and Canada for your drug development strategy. With an understanding of how regulatory agencies and market environments may differ, you will be in a better position to optimize your program. In Altasciences’ on-demand webinar, A Hop Across the Pond, Ingrid Holmes, Vice President of Global Clinical Operations, and Dr.
A Unique Approach to Project Management
The Benefits of Altasciences’ Unique Approach to Project Management
When you partner with Altasciences, you are assigned a dedicated
cross-functional project manager to seamlessly guide you from one milestone to the next — keeping your studies on track, throughout the lifecycle of your project.
In this complimentary webinar, learn about the benefits of Altasciences’ unique program management offering, including case studies and client testimonials.
You may also be interested in the following:
- Fact Sheet: Integrated Research Services
- Video: QUICK CHAT with Lauren Szczurowski — A Seamless Experience with Scientific Project Management
- Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single service or a synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Planning a Human Abuse Potential Clinical Trial?
HAP Capabilities at Our Kansas City Clinical Facility
Altasciences is a CNS Center of Excellence for research from discovery to preclinical to clinical. We have experience in a diverse range of human abuse potential (HAP) studies, such as for stimulants, opioids, and sedative hypnotics; and have conducted over 60 HAP trials over the last decade.
Sponsors choose our Kansas City Research Campus for their HAP studies for our:
- Experienced physicians who understand how to work with recreational drug users
- 36-bed specialty clinical unit in Kansas City for sequestering patient populations
- Upscale facilities that contribute to industry-leading retention rates for up to 60 days of consecutive confinement
- Pharmacies with USP 797 clean room with Class II biological safety cabinet
- Database of over 400,000 active participants including 45,000 at our Kansas City site alone. The database includes recreational abusers of opioids, stimulants, sedative hypnotics, and cannabinoids
Discover more!
You may also be interested in the following:
- Webpages:
- Video:
Join our upcoming webinars:
- Inside the Pharmacodynamic Toolbox: How Questionnaires, Models, and Tests of Cognition Can Accelerate the Development of CNS-Active Drugs
- Ethnobridging in Phase I Clinical Trials: Strategy for Enhancing Asset Value and Accelerating Global Drug Development
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Did you know? Altasciences has 8 locations in North America
Altasciences’ Clinical Facilities Move in Unison
Altasciences provides strategically located clinical pharmacology facilities and access to over 500 beds across North America. We have over 1,000 employees dedicated to clinical pharmacology research who conduct over 285 trials per year.
Operations at our clinical teams in Los Angeles, Kansas City, and Montreal follow the same set of standard operating procedures to offer you a scientifically sound, quality experience, every time — for both your single-site or multi-site studies.
In addition, our clinical teams work in unison with our preclinical, bioanalytical, manufacturing, and research support teams at our five other sites, to offer an integrated drug development solution, from lead candidate selection to clinical proof of concept, and beyond.
Altasciences provides customized solutions that fit your needs, and innovative in-house recruitment call centers for quick study startup.
Let’s get started!
You may also be interested in the following:
- Video: Fully Integrated Drug Development Solutions
- Webpage: Phase 1 Clinical Trial Units
- E-book: First-in-Human Solution
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
PODCAST — How a Common Injury Turns Into an Addiction
Episode 2 — The Many Faces of Recreational Drug Use
Prescription drug abuse has been an ongoing public health concern in North America. In this second episode of "Chasing the Dragon — A Series of Candid Interviews with Opioid and Stimulant Recreational Drug Users”, you will hear from an individual who began using opioids following a back injury. Then, Altasciences’ Dr. Beatrice Setnik, CSO, and Dr. Debra Kelsh, Psychiatrist and Principal Investigator, provide a unique perspective around the behaviors of drug abuse.
In case you missed it, watch Episode 1 here.
Speak with an expert about your research needs.
You may also be interested in the following:
- The Altascientist: CNS-Active Drugs — Complex Considerations
- Webpage: Human Abuse Potential Capabilities
- E-book: First-In-Human Solution
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.